Elsevier

Vaccine

Volume 19, Issues 28–29, 16 July 2001, Pages 3927-3935
Vaccine

Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice

https://doi.org/10.1016/S0264-410X(01)00119-0Get rights and content

Abstract

The use of Lactococcus lactis as an antigen delivery vehicle for mucosal immunisation has been proposed. To determine whether L. lactis could effectively deliver Helicobacter pylori antigens to the immune system, a recombinant L. lactis expressing H. pylori urease subunit B (UreB) was constructed. Constitutive expression of UreB by a pTREX1 vector resulted in the intracellular accumulation of UreB to ≈6.25% of soluble cellular protein. Five different oral regimens were used to vaccinate C57BL/6 mice and the immune response measured. One regimen, which consisted of four weekly doses of 1010 bacteria, followed after an interval of ≈4 weeks by three successive daily doses, was able to elicit a systemic antibody response to UreB in the mice, although subsequently, a similar regimen produced a significant antibody response in only one out of six mice. The other three regimes, in which mice were vaccinated with two or three sets of three consecutive daily doses of recombinant bacteria over 30 days, failed to elicit significant anti-UreB serum antibody responses. In three regimens, the immunised mice were then challenged by H. pylori strain SS1 and no protective effect was observed. These findings suggest that any adjuvant effects of L. lactis are unlikely to be sufficient to produce an effective immune response and to protect against H. pylori challenge, when used to deliver a weak immunogen, such as UreB.

Introduction

Helicobacter pylori is now recognised as the most widespread human pathogen. Approximately half of the world's population is infected [1], [2]. Infection with H. pylori is highly associated with chronic active gastritis, peptic ulcers, gastric adenocarcinoma and more rarely, lymphoma of the mucosa-associated lymphoid tissue (MALT) [3], [4], [5]. Current antibiotic-based triple therapies are not practical for global control due to the high cost, problems with patients’ compliance and the emergence of antibiotic-resistant strains [1], [6]. Vaccination against H. pylori has therefore been considered to control H. pylori infection and it has been shown that administration of oral bacterial antigens, mainly urease, together with a mucosal adjuvant can protect mice against Helicobacter infection [6], [7], [8], [9]. Urease is acid stable, appears to be essential for gastric colonisation by H. pylori and is expressed by all clinical strains of H. pylori. Cross-reactivity is present between the ureases of different H. pylori strains or between the ureases of H. pylori and animal strain — H. felis [10]. The urease gene structural subunits A and B (ureAB) have been cloned and expressed in Escherichia coli [11]. Both subunit proteins (UreA and UreB) are immunogenic in combination with a mucosal adjuvant, but UreB seems to be more protective than UreA [12], [13]. Cholera toxin (CT) or E. coli labile toxin (LT) has been used in all successful oral immunisation models. No protection was achieved when antigens were administered without a mucosal adjuvant [14]. CT cannot be given to humans and the use of LT is limited due to its known toxicity in a human volunteers study [15]. A genetically detoxified LT mutant, LTK63, has been used in vaccine studies with promising results, although its safety for human use is still being investigated [9].

The attenuated Salmonella typhimurium aro and phoPC mutants strains expressing UreA and UreB have been used in mouse protection experiments [16], [17]. However, human volunteers orally vaccinated with phoP/phoQ-deleted S. typhi expressing H. pylori UreA and UreB developed gastroenteritis-like syndrome of a variable degree [18]. Live attenuated Salmonella strains are still able to establish a limited infection in man and cannot be used for vulnerable groups, such as infants, elderly people and the immunocompromised patients.

By contrast, the use of Lactococcus lactis to deliver protective antigens to the mucosal surfaces may be an alternative way to avoid these problems. L. lactis does not require mucosal antigens, such as CT or LT and is not capable of establishing an infection in man. L. lactis is a Gram-positive food-grade bacterium and has a long history of widespread use in the food industry for the production of fermented milk products [19]. It does not colonise the digestive tract of man or animals, but can survive passage through the gut [20], [21]. It has been suggested that antigens expressed by L. lactis are presented to the immune system in particulate form and may therefore be less likely to induce oral tolerance than soluble antigens. Furthermore, L. lactis is approximately the same size as biodegradable microparticles that are known to be taken up by M cells and have been shown to be capable of acting as effective oral vaccine vehicles [22]. The use of the live vaccine carrier does not require antigen purification or the combined use of a mucosal adjuvant and it can bypass the degradation and denaturation of antigens in the stomach. L. lactis expressing tetanus toxin fragment C (TTFC) has been used successfully for oral immunisation against tetanus toxin challenge in the mouse model [23]. In addition, oral inoculation of this TTFC expression strain elicited local immunoglobulin A (IgA) responses in the gut secretions [23].

In this study, we used recombinant DNA techniques to clone H. pylori protein UreB and this protein was expressed in L. lactis MG1363 via an expression vector, pTREX1. This recombinant L. lactis expressing UreB was used to vaccinate C57BL/6 mice by the oral route to evaluate the mucosal and systemic antibody responses to UreB in a mouse model. Vaccinated mice were then challenged with H. pylori to determine the extent of any protection provided by vaccination.

Section snippets

Bacterial strains and growth conditions

L. lactis MG1363 was grown in M17 medium (Oxoid, Basingstoke, UK) containing 0.5% (w/v) glucose (Sigma) (GM17) at 30°C aerobically. H. pylori SS1 was stored at −70°C in Tryptone Soya broth (TSB) (Oxoid) containing 25% glycerol, until required. For mouse challenge experiments, H. pylori was grown on Dent plates (Blood Agar Base No. 2; Oxoid) supplemented with 7% (v/v) defibrinated horse blood (Oxoid), Dent selective supplement (Oxoid) and incubated at 37°C under microaerophilic conditions (4% O2

Cloning and expression of H. pylori UreB into L. lactis MG1363

The gene encoding the urease subunit B of H. pylori (1769 nucleotides) was PCR-amplified and cloned as a SphI-BamHI fragment in the expression plasmid pTREX1 generating pTREX1::ureB. The inserted SphI site at the 3′ end of ureB resulted in an alteration of the amino acid residue at position +2 from lysine to arginine. This modification was expected to have a negligible effect on the conformation of the N-terminus extremity of UreB as they are both positive amino-acid residues.

In vitro and in vivo stability of the ureB construct

The pTREX1::ureB

Discussion

Our results demonstrate for the first time that L. lactis is able to produce substantial quantities of a H. pylori antigen in soluble form. L. lactis has been shown to be able to produce the subunit B of the urease (UreB) organism, H. pylori, in the Gram-positive L. lactis. Although over-expression level of certain proteins and antigens may result in the death of cells [25], the use of the constitutive expression vector, pTREX1, enabled us to reach a UreB production level of 6.25% without

Acknowledgements

We thank Jeremy Wells for the gift of L. lactis MG1363 and pTREX1, Peter Jenks for H. pylori SS1 and Harry Kleanthous (OraVax) for recombinant urease.

References (32)

  • M.J. Blaser et al.

    Association of infection due to Helicobacter pylori with specific gastrointestinal pathology

    Rev. Infect. Dis.

    (1991)
  • D. Forman et al.

    Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation

    Br. Med. J.

    (1991)
  • T. Hussel et al.

    The response of cells from low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue to Helicobacter pylori

    Lancet

    (1993)
  • P. Michetti

    Vaccine against Helicobacter pylori: fact or fiction?

    Gut

    (1997)
  • H. Kleanthous et al.

    Rectal and intranasal immunisations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection

    Infect. Immun.

    (1998)
  • P.R. Hawtin et al.

    Investigation of the structure and localisation of the ureases of Helicobacter pylori using monoclonal antibodies

    J. Gen. Microbiol.

    (1990)
  • Cited by (98)

    • Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes

      2015, Veterinary Microbiology
      Citation Excerpt :

      Importantly, the surface display of the antigen on Lactobacillus showed better effects than its intracellular display for mucosal vaccine (Lee et al., 2000). However, in addition to the mucosal delivery vehicle, various methods have been studied to optimize mucosal immunogenicity, such as the application of different adjuvants and the display of antigen on different locations (surface, cytoplasm and extracellular) (Lee et al., 2001; Robinson et al., 2004). Among the methods of vaccine development strategies, vaccine with an appropriate adjuvant via an appropriate route seems to be the best choice for eliciting antigen-specific immune responses.

    View all citing articles on Scopus

    This work was presented in part at the Twelfth International Meeting of the European Helicobacter pylori Study Group Workshop on Gastroduodenal Physiology and Helicobacter pylori, 1–4 September, 1999, Helsinki, Finland.

    View full text